Gleneagle Gold Ltd (ASX:GLN) is in the final stages of its transition into the medical cannabis sector through the reverse takeover of Zelda Therapeutics.
Zelda was spun out of a successful US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.
Zelda has exclusive, global access to an extensive set of human data related to medicinal cannabis-based formulations and treatment protocols.
This human data has been generated over several years by the Aunt Zelda’s group.
Aunt Zelda’s has a very high profile within the USA and a growing international profile based upon its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.
Zelda has been granted a worldwide, exclusive and perpetual licence to this data, related systems, formulations and treatment protocols by the Aunt Zelda’s group.
Zelda will use this information to design a series of Phase 2-ready human clinical trials which the company is confident will be successful given the existing patient experiences and treatment outcomes.
Find out more from Dr. Stewart Washer, executive director, at Proactive's Spotlight CEO Sessions in Sydney in August 2016.
REGISTER HERE, CLICK ON LINK: Sydney Investor Sessions, Wednesday, 3rd August
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.